Approval · Notice of Compliance 29686 · 2022
ULTOMIRIS: Notice of Compliance 29686
Issued December 13, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29686
- Date
- December 13, 2022
- Company
- Alexion Pharma GmbhBaar, --, Switzerland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength
Products in this notice
Medicinal ingredients
- RAVULIZUMAB 300 MG per 3ML
- RAVULIZUMAB 100 MG per ML